Oncology – Breast
Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial.
24 Jan, 2022 | 08:08h | UTCOutcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Related:
Commentary on Twitter:
In MINDACT, 15% of the pts (n=1000) had an ultra-low 70-gene signature. Although some had tumors >2 cm (20%) & were LN+ (20%), prognosis was outstanding
8-year DMFI 97%
8-year BCSS 99.6%Most of these patients received adj treatment. Did they need it?https://t.co/V9SH2StuQE
— Paolo Tarantino (@PTarantinoMD) January 22, 2022
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
20 Jan, 2022 | 08:57h | UTC
Commentary on Twitter
Out on @JCO_ASCO the new ASCO/OH guidelines for adjuvant bisphosphonates in BC
Important to weight risks and benefits based on the risk profile of the disease, financial toxicity, drug availability, patient preferences, comorbidities & life expectancy. https://t.co/6noyYplALB
— Paolo Tarantino (@PTarantinoMD) January 18, 2022
M-A: Beta-blockers and renin–angiotensin system inhibitors may provide a modest benefit for the preservation of left ventricular function in patients with breast cancer treated with anthracyclines or trastuzumab.
19 Jan, 2022 | 08:34h | UTCA systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer – European Journal of Cardiology (link to abstract – $ for full-text)
Commentary: BBs, ACEI/ARBs to Prevent LV Dysfunction Due to Breast Cancer Drugs – American College of Cardiology
Adjuvant Capecitabine for early breast cancer: 15-year overall survival results from a randomized trial.
18 Jan, 2022 | 09:11h | UTC
Final overall survival analysis of the HER2CLIMB RCT: Tucatinib vs. placebo added to Trastuzumab and Capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases.
13 Jan, 2022 | 08:12h | UTCTucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis – Annals of Oncology (link to abstract – $ for full-text)
Original Study: Randomized Trial: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
RCT: In premenopausal women with breast cancer, gonadotropin-releasing hormone analogs may preserve ovarian function against chemotherapy-induced gonadotoxic effects.
11 Jan, 2022 | 02:26h | UTCEffects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Randomized clinical trial finds administration of gonadotropin-releasing hormone analogs (GnRHa) with chemotherapy in premenopausal pts with #BreastCancer reduces risk of premature ovarian insufficiency (#POI) and promotes recovery of ovarian function. https://t.co/gymbKT9GWZ pic.twitter.com/OUOlIwPSsq
— JAMA Oncology (@JAMAOnc) December 30, 2021
RCT: In patients presenting with metastatic breast cancer, early locoregional therapy for the primary site did not improve survival or quality of life.
11 Jan, 2022 | 02:29h | UTCEarly Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Systematic Review: Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer.
9 Dec, 2021 | 10:08h | UTC
Commentary on Twitter (thread – click for more)
https://twitter.com/ccaneloa/status/1464655542010494981
RCT: 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.
2 Dec, 2021 | 09:49h | UTC21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Among postmenopausal women with HR–positive, HER2-negative breast cancer, 1-3 positive lymph nodes, and a 21-gene recurrence score of 25 or lower, 5-year invasive disease–free survival was similar whether they received endocrine or chemoendocrine therapy. https://t.co/aZLXBvSHHl pic.twitter.com/EBVnMkGHx4
— NEJM (@NEJM) December 2, 2021
Advances in Breast Cancer Radiotherapy: Implications for Current and Future Practice.
30 Nov, 2021 | 09:55h | UTC
Commentary on Twitter
Advances in #BreastCancer radiotherapy allow shorter regimens and reduced toxicities. This #JCOOP Clinical review summarizes the latest evidence in #radonc for #bcsm @CshahMD ➡️ https://t.co/JxvU5FSQlv pic.twitter.com/GOcwAFJzRm
— Journal of Clinical Oncology (@JCO_ASCO) October 31, 2021
RCT: An exercise program reduced upper limb disability one year after non-reconstructive breast cancer surgery.
18 Nov, 2021 | 08:39h | UTCCommentaries:
Exercise reduces upper limb disability after breast cancer surgery – BMJ / News Medical
Exercise Helps Ease Arm, Shoulder Pain After Breast Cancer Surgery- HealthDay
Structured Exercise Improves Upper Limb Function After Breast Ca Surgery – Physician’s Weekly
Commentary on Twitter
Women who exercise shortly after having non-reconstructive breast cancer surgery appear to regain better shoulder and arm mobility and experience less pain than those who receive standard care, finds this study @jxbruce https://t.co/BhIKb8RRjV
— The BMJ (@bmj_latest) November 11, 2021
Review: Treatment landscape of triple-negative breast cancer — expanded options, evolving needs.
16 Nov, 2021 | 08:23h | UTCTreatment landscape of triple-negative breast cancer — expanded options, evolving needs – Nature Reviews Clinical Oncology (free for a limited period)
Commentary on Twitter
A Review in @NatRevClinOncol describes the current and upcoming therapeutic landscape of triple-negative breast cancer. https://t.co/bcFTef01t1 pic.twitter.com/zFPyeeCnD5
— Nature Portfolio (@NaturePortfolio) November 15, 2021
Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer.
11 Nov, 2021 | 08:32h | UTC
Large observational study suggests prolactin-increasing antipsychotics are associated with increased risk of breast cancer (OR=1.56 for over 5 years of exposure); prolactin-sparing antipsychotics (including clozapine, quetiapine, or aripiprazole), on the other hand, were not associated with increased risk.
10 Nov, 2021 | 06:57h | UTCAntipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
Nested case-control study: ≥5 years exposure to prolactin-sparing APDs was not associated with an increased risk of breast cancer vs.<1 year exposure (aOR=1.19; 0.90–1.58). The opposite was observed with APDs that increase prolactin (aOR=1.56; 1.27–1.92) https://t.co/LwCVyTH051
— P𝘧OL (@psychopharmacol) September 12, 2021
Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care.
9 Nov, 2021 | 01:44h | UTCRelated:
2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients
FDA Pooled Analysis: Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant.
9 Nov, 2021 | 01:05h | UTCOverall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
A pooled analysis of phase III trials of fulvestrant plus either CDK4/6 inh or placebo in pts with HR+/HER2- advanced-stage #breastcancer shows an mOS benefit of 7.1 months (over a mFU of 43.7 months) favouring CDK4/6i (HR 0.77, 95% CI 0.68–0.88): https://t.co/ZMa0J8gS8Q #bcsm
— NatureRevClinOncol (@NatRevClinOncol) October 21, 2021
RCT: Elective internal mammary node irradiation does not increase disease-free survival or overall survival in most women with node-positive breast cancer.
27 Oct, 2021 | 01:28h | UTCEffect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial – JAMA Oncology (free for a limited period)
Commentary: No Survival Benefit for Internal Mammary Node Irradiation in Breast Cancer — Women with medially or centrally located tumors may be candidates, however, says researcher – MedPage Today (free registration required)
Commentary on Twitter
Phase III randomized study evaluated the role of internal mammary node irradiation (IMNI) in node-positive #breastcancer. IMNI did not improve the DFS in unselected patients, but did improve DFS in patients with medially or centrally located tumors https://t.co/tw4ZrHn5wn pic.twitter.com/34ye3TR9MA
— JAMA Oncology (@JAMAOnc) October 25, 2021
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
21 Oct, 2021 | 09:48h | UTCPress release: metastatic breast cancer: new ESMO guideline with evidence-based recommendations – European Society of Medical Oncology
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomized trials.
15 Oct, 2021 | 02:07h | UTC
Commentary on Twitter
https://twitter.com/NicoleKuderer/status/1423002503138795521
Cohort Study: Women treated with radiation therapy for left-sided breast cancer had over twice the risk of subsequent coronary artery disease compared with women treated with radiation therapy for right-sided breast cancer.
1 Oct, 2021 | 10:21h | UTCCommentaries:
CAD in Young Women After Radiation Therapy for Breast Cancer – American College of Cardiology
Commentary on Twitter
According to a study from #JACCCardioOnc, women with left-sided breast cancer undergoing radiation therapy between 1985 and 2008 had over twice the risk of subsequent #cvCAD compared to women with right-sided breast cancer. Learn more here: https://t.co/5q9tToSSRp #CardioOnc
— American College of Cardiology (@ACCinTouch) September 22, 2021
Systematic Review: Partial breast irradiation versus whole breast radiotherapy for early breast cancer.
15 Sep, 2021 | 08:46h | UTC
Commentary on Twitter
https://twitter.com/CochraneUK/status/1433703573402046467
Long-term report of study evaluating radiation following surgical excision for good-risk ductal carcinoma in situ.
14 Sep, 2021 | 08:44h | UTC
Commentary on Twitter
At 15 years, NRG-RTOG 9804 "good risk" breast #DCIS trial shows advantage of radiation therapy over observation to reduce #breastcancer risk https://t.co/l5OWVOb5Dg
#JCO #BCSM #radonc @NRGOnc; @MSK_RadOnc pic.twitter.com/TPAZRheoHT— Journal of Clinical Oncology (@JCO_ASCO) September 10, 2021
Review: neoadjuvant endocrine therapy in clinical practice.
12 Sep, 2021 | 21:34h | UTCNeoadjuvant Endocrine Therapy in Clinical Practice: A Review – JAMA Oncology (free for a limited period)
Systematic review finds there is insufficient evidence that AI breast cancer screening is accurate enough to replace human scrutiny.
10 Sep, 2021 | 05:12h | UTCOriginal study: Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy – The BMJ
Commentary on Twitter
A systematic review of #AI for mammography is very disappointing
"Thirty four (94%) of 36 AI systems evaluated in these studies were less accurate than a single radiologist, and all were less accurate than consensus of two or more radiologists"https://t.co/zqFTxojU9J @bmj_latest pic.twitter.com/wylwOsf4ua— Eric Topol (@EricTopol) September 2, 2021
Cohort study: Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers.
20 Aug, 2021 | 08:39h | UTC
Commentary on Twitter
For #BRCA1 mutation carriers, longer duration of oral contraceptive use (>10 yr) is associated with a greater reduction in #OvarianCancer risk, and the protection is long term. https://t.co/HrrutgaYKX
— Anna Chichura, MD (@AnnaChichuraMD) July 3, 2021